Julie HENRIQUES  is a research engineer in biostatistics. She passed in 2010 a master’s degree in statistical modeling at the University of Franche-Comté. During the master’s degree’s internship in the biostatistics service of the Hospices Civils of Lyon, she realized a  study on the correction of survival estimates in the context of loss to follow-up in HIV cohort .  She worked as independent statistician for 5 years and participated to projects in many area such as financial times series, reservoir computing or EEG signal processing.
 
In 2015, she joined the Methodology and quality of life unit in Oncology (UMQVC) at the University hospital of Besancon.



Derniers articles

sample

AbstractSmall bowel adenocarcinoma (SBA) is a rare tumour. We conducted a prospective cohort to describe the prevalence,...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Int J Cancer

sample

AbstractIntroduction: Regorafenib (R) and trifluridine/tipiracil (FTD/TPI) are of proven efficacy in metastatic...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Clinical colorectal cancer

sample

AbstractAnti-EGFR efficacy in patients with microsatellite instability (MSI) metastatic colorectal cancer (mCRC)...

Posté par : Dr. Dewi VERNEREY, Mme. Julie HENRIQUES
Nom de la revue : J Natl Cancer Inst

sample

AbstractBackground: Patients with RAS wild-type (WT) nonresectable metastatic colorectal cancer (mCRC) may receive...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Oncologist

sample

AbstractIn metastatic pancreatic adenocarcinoma, a high neutrophil-to-lymphocyte ratio (NLR) at diagnosis is a marker of...

Posté par : Dr. Dewi VERNEREY, Mme. Julie HENRIQUES
Nom de la revue : Clin Res Hepatol Gastroenterol

sample

AbstractPurpose: Circulating tumor DNA (ctDNA) has been suggested as a major prognostic factor in resected stage...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Clin Cancer Res .

sample

AbstractBackground: Studies have reported a beneficial role of the addition of trastuzumab to platin-5-FU based...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Frontiers in oncology

sample

AbstractSmall bowel adenocarcinoma (SBA) is a rare tumour. Large genomic analyses with prognostic assessments are...

Posté par : Dr. Dewi VERNEREY, Mme. Julie HENRIQUES
Nom de la revue : Int J Cancer

sample

AbstractBackground: In 2013, the interim analysis of the Protocol for Herceptin as Adjuvant therapy with Reduced...

Posté par : Dr. Sophie PAGET-BAILLY, Mme. Julie HENRIQUES
Nom de la revue : Lancet

sample

AbstractAim: Raltitrexed (RTX) is a thymidylate synthase inhibitor with large pharmacokinetics (PK) variability...

Posté par : Dr. Dewi VERNEREY, Mme. Julie HENRIQUES
Nom de la revue : Br J Clin Pharmacol

2015-2024 © Copyright - UMQVC.org

Website by Pearlweb